Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use

Keratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA i...

Full description

Saved in:
Bibliographic Details
Main Authors: Jason E. Cohn, Hilary M. Caruso Sales, Giang Huong Nguyen, Harvey Spector, Kenneth Briskin
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Case Reports in Pathology
Online Access:http://dx.doi.org/10.1155/2017/8257590
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832565272443092992
author Jason E. Cohn
Hilary M. Caruso Sales
Giang Huong Nguyen
Harvey Spector
Kenneth Briskin
author_facet Jason E. Cohn
Hilary M. Caruso Sales
Giang Huong Nguyen
Harvey Spector
Kenneth Briskin
author_sort Jason E. Cohn
collection DOAJ
description Keratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA involving the nasal septum, possibly related to ranibizumab use. A flesh-colored lesion on the right anterior nasal septum lesion was visualized on examination. Histologic examination revealed a well-circumscribed, dome-shaped central crater filled with keratin, well-differentiated squamous epithelium with ground-glass cytoplasm with pushing margins, and intraepithelial microabscesses establishing the diagnosis of KA. KA of the nasal septum has only been reported once in the literature. This case is unusual because it normally presents on sun-exposed areas. Additionally, this patient was taking ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor for macular degeneration. Despite ranibizumab not being directly linked to precancerous and cancerous skin lesions, agents in this medication class have been. Although it is difficult to prove associations in this isolated case, the role of ranibizumab causing cutaneous lesions should be further investigated.
format Article
id doaj-art-ee7bb8c6894f4ababd06ebfdc1b108b9
institution Kabale University
issn 2090-6781
2090-679X
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Case Reports in Pathology
spelling doaj-art-ee7bb8c6894f4ababd06ebfdc1b108b92025-02-03T01:08:55ZengWileyCase Reports in Pathology2090-67812090-679X2017-01-01201710.1155/2017/82575908257590Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab UseJason E. Cohn0Hilary M. Caruso Sales1Giang Huong Nguyen2Harvey Spector3Kenneth Briskin4Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, 4190 City Line Avenue, Philadelphia, PA, USADepartment of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, 4190 City Line Avenue, Philadelphia, PA, USADepartment of Dermatology, University of Colorado Anschutz Medical College, 1665 Aurora Court, Aurora, CO, USADepartment of Pathology, Crozer-Chester Medical Center, One Medical Center Boulevard, Upland, PA, USADepartment of Otolaryngology-Head and Neck Surgery, Crozer-Chester Medical Center, One Medical Center Boulevard, Upland, PA, USAKeratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA involving the nasal septum, possibly related to ranibizumab use. A flesh-colored lesion on the right anterior nasal septum lesion was visualized on examination. Histologic examination revealed a well-circumscribed, dome-shaped central crater filled with keratin, well-differentiated squamous epithelium with ground-glass cytoplasm with pushing margins, and intraepithelial microabscesses establishing the diagnosis of KA. KA of the nasal septum has only been reported once in the literature. This case is unusual because it normally presents on sun-exposed areas. Additionally, this patient was taking ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor for macular degeneration. Despite ranibizumab not being directly linked to precancerous and cancerous skin lesions, agents in this medication class have been. Although it is difficult to prove associations in this isolated case, the role of ranibizumab causing cutaneous lesions should be further investigated.http://dx.doi.org/10.1155/2017/8257590
spellingShingle Jason E. Cohn
Hilary M. Caruso Sales
Giang Huong Nguyen
Harvey Spector
Kenneth Briskin
Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use
Case Reports in Pathology
title Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use
title_full Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use
title_fullStr Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use
title_full_unstemmed Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use
title_short Keratoacanthoma of the Nasal Septum Secondary to Ranibizumab Use
title_sort keratoacanthoma of the nasal septum secondary to ranibizumab use
url http://dx.doi.org/10.1155/2017/8257590
work_keys_str_mv AT jasonecohn keratoacanthomaofthenasalseptumsecondarytoranibizumabuse
AT hilarymcarusosales keratoacanthomaofthenasalseptumsecondarytoranibizumabuse
AT gianghuongnguyen keratoacanthomaofthenasalseptumsecondarytoranibizumabuse
AT harveyspector keratoacanthomaofthenasalseptumsecondarytoranibizumabuse
AT kennethbriskin keratoacanthomaofthenasalseptumsecondarytoranibizumabuse